Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018
Dec 31, 2017
Total Revenue
391,706
372,845
373,447
358,305
Cost of Revenue
78,893
79,019
82,333
75,995
Gross Profit
312,813
293,826
291,114
282,310
Operating Expenses
Research Development
161,408
175,582
183,948
168,608
Selling General and Administrative
148,566
153,280
138,336
160,280
Non Recurring
--
--
--
--
Others
18,580
10,227
13,202
20,375
Total Operating Expenses
328,554
339,089
335,486
349,263
Operating Income or Loss
(15,741)
(45,263)
(44,372)
(66,953)
Income from Continuing Operations
Total Other Income/Expenses Net
2,121
22,742
(104)
128,393
Earnings Before Interest And Taxes
(8,290)
(17,958)
(47,843)
62,537
Interest Expense
11,123
11,219
2,961
7,939
Income Before Tax
(19,413)
(29,177)
(50,804)
54,598
Income Tax Expense
(6,793)
(12,385)
(6,655)
105,990
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(12,620)
(16,792)
(44,149)
(51,392)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(12,620)
(16,792)
(44,149)
(51,392)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(12,620)
(16,792)
(44,149)
(51,392)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information